In the early trading session on June 5th, the A-share and Hong Kong stock markets continued their adjustments, with innovative drug assets showing relative resilience. Over the previous four trading sessions, A-H share innovative drug stocks had declined consecutively, pushing the intraday prices of the Huabao Pharma ETF (562050), heavily weighted in A-share innovative drugs, and the fully-invested Huabao Hong Kong Stock Connect Innovative Drug ETF (520880) to repeated historical lows.
The A-share pharmaceutical sector saw a significant rebound, with both innovative drugs and traditional Chinese medicine contributing to gains. The Huabao Pharma ETF (562050), the only fund tracking the pharmaceutical index, surged over 2.18% at one point and is currently up more than 1%. Among its constituents, Zhejiang NHU Co., Ltd. and Betta Pharmaceuticals Co., Ltd. led the gains, rising over 4%.
Hong Kong Stock Connect innovative drug stocks initially rose but later retreated. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which invests 100% in innovative drug R&D targets, opened higher and climbed as much as 1.74% intraday, but was up only 0.25% at the time of writing. Key constituent Kelun-Biotech Biopharmaceutical Co., Ltd. gained over 3%, Innovent Biologics, Inc. rose over 1%, while a decline of 1.8% in Akeso, Inc. was a primary drag. BeiGene, Ltd. and 3SBio Inc. also traded in the red.
Notably, the Hong Kong Stock Connect innovative drug sector has recently accelerated its bottoming process, attracting leveraged funds to accumulate high-value positions at lower levels. As of June 4th, the margin balance for the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880) reached 105 million yuan, setting a new historical record.
Market analysts suggest the current volatility in the innovative drug sector is driven more by trading dynamics than a reversal of the industry's long-term fundamentals. From a medium- to long-term perspective, the global competitiveness of China's innovative drug industry remains intact. It is recommended to consider using ETF tools to position in leading platform companies with global business development capabilities and scarce core pipelines during periods of lower market volatility and subdued sentiment.
For pure exposure to innovative drugs, the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880) offers 100% allocation to innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, highlighting its focus on industry leaders. The underlying assets are Hong Kong-listed stocks, offering high volatility and T+0 settlement.
For investors seeking to reduce volatility, the Huabao Pharma ETF (562050) provides a unique allocation with "70% innovative drugs + 30% traditional Chinese medicine," a rare combination in the market that blends the high growth potential of innovative drugs with the high dividend appeal of traditional Chinese medicine.
Data is sourced from the Shanghai, Shenzhen, and Hong Kong stock exchanges, China Securities Index Co., Ltd., and Hang Seng Indexes Company.
Note: ETF funds do not charge sales service fees. When subscribing for or redeeming fund units, subscription and redemption agents may charge a commission of up to 0.5%, which includes relevant fees charged by stock exchanges and registration institutions. Please refer to each fund's legal documents for specific fee details.
Risk Disclosure: Constituent stocks mentioned are for illustrative purposes only. Descriptions of individual stocks do not constitute investment advice in any form, nor do they represent the holdings or trading intentions of any fund managed by the fund manager. The fund manager assesses the risk rating of the Huabao Pharma ETF and its feeder fund as R3 - Medium Risk, suitable for Balanced (C3) and above investors. The risk rating for the Huabao Hong Kong Stock Connect Innovative Drug ETF and its feeder fund is assessed as R4 - Medium to High Risk, suitable for Aggressive (C4) and above investors. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors are solely responsible for their independent investment decisions. Furthermore, any views, analyses, or forecasts herein do not constitute investment advice of any kind to readers, and no responsibility is accepted for any direct or indirect losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future results. Fund investment carries risks.
Comments